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Context—Inhaled hypertonic saline is recommended as therapy for cystic fibrosis (CF) patients 6
years of age and older, but its efficacy has never been evaluated in CF patients <6 years of age.
Objective—To determine if hypertonic saline reduces the rate of protocol-defined pulmonary
exacerbations in CF patients <6 years of age.
Design and Setting—A multicenter, randomized, double-blind placebo-controlled trial was
conducted from April 2009 to October 2011 at 30 CF care centers in the United States and
Canada.
Participants—Participants had an established diagnosis of CF and were 4 to 60 months of age.
A total of 344 patients were assessed for eligibility; 321 participants were randomized; 29 (9%)
withdrew prematurely.
Intervention—The active group (n=158) received 7% hypertonic saline and the control group
(n=163) received 0.9% isotonic saline nebulized twice daily for 48 weeks. Both groups received
albuterol or levalbuterol prior to each study drug dose.
Main Outcome Measures—the rate of protocol-defined pulmonary exacerbations during the
48 week treatment period treated with oral, inhaled or intravenous antibiotics.
Results—The mean pulmonary exacerbation rate (events/person-year) was 2.3 (95% CI, 2.0, 2.5)
in the hypertonic saline group and 2.3 (95% CI, 2.1, 2.6) in the isotonic saline group; the rate ratio
was 0.98 (95% CI, 0.84, 1.14)). Among participants with pulmonary exacerbations, the mean
number of total antibiotic treatment days for a pulmonary exacerbation was 60 (95% CI 49, 70) in
the hypertonic saline group and 52 (95% CI 43, 61) in the isotonic saline group. There was no
significant difference in secondary endpoints including height, weight, respiratory rate, oxygen
saturation, cough or respiratory symptom scores. Infant pulmonary function testing performed as
an exploratory outcome in a subgroup (N=73, with acceptable measurements at 2 visits in 45) did
not demonstrate significant differences between groups except for the mean change in forced
expiratory volume in 0.5 seconds which was 38 ml greater (95% CI 1, 76) in the hypertonic saline
group.
Adherence by returned study drug ampoules was at least 75% in each group. Adverse event
profiles were also similar, with the most common adverse event of moderate or severe severity in
each group being cough (39% of hypertonic saline group, 38% of isotonic saline group).
Conclusions—Among infants and children with cystic fibrosis less than 6 years old, the use of
inhaled hypertonic saline compared with isotonic saline did not reduce the rate of pulmonary
exacerbations over 48 weeks of treatment.
Trial Registration—www.clinicaltrials.gov NCT00709280
INTRODUCTION
The hallmark features of cystic fibrosis (CF) lung disease include airway infection,
inflammation, obstruction, and structural lung damage. These abnormalities begin in
infancy, often prior to the onset of symptoms, and progress over the first years of life1–4.
Thus, early initiation of effective chronic therapies, an opportunity afforded by newborn
screening, could potentially delay or prevent progression of CF lung disease. There are no
clinical trials of chronic non-antibiotic maintenance pulmonary therapies in infants and
preschoolers with CF, even though this is the population with the greatest potential for long-
term benefit.
Dysfunctional ion transport leads to reduced airway surface liquid (ASL) volume in CF and
reduction in mucociliary clearance 5. Retained mucus serves as a nidus for chronic infection
and exaggerated, sustained neutrophilic inflammation causing progressive airway
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obstruction and bronchiectasis 6. Hypertonic saline has been demonstrated to increase
airway surface liquid in bronchial epithelial cells in vitro and to improve defective
mucociliary clearance in CF patients.7, 8
A clinical trial in older children and adults with CF demonstrated modest effects on lung
function and a significant decrease in pulmonary exacerbations9, resulting in widespread use
of this therapy in older children and adults with CF. Given its mechanism of action,
hypertonic saline is an attractive agent for early intervention trials. While 3 short-term safety
studies of 7% hypertonic saline have been conducted in CF patients <6 years of age10–12, its
efficacy and long-term safety in this population have not been evaluated. Given that
hypertonic saline use increased from 6% to 19% among U.S. children with CF 2 to 5 years
of age during the enrollment period (2007–2010)13, there was a “window of opportunity” to
conduct a clinical trial before hypertonic saline use became widespread in this age range.
We conducted a randomized controlled trial of 7% hypertonic saline among children with
CF <6 years of age, to our knowledge the first multicenter clinical trial of a non-
antimicrobial chronic CF therapy in this age range. We hypothesized that hypertonic saline
would decrease the rate of pulmonary exacerbations and be safe in young children with CF.
METHODS
Overview
This was a 30-center, randomized, parallel group, double blind, controlled trial of 7%
hypertonic saline (active drug) vs. 0.9% isotonic saline (control agent) inhaled twice daily
for 48 weeks among children with an established diagnosis of CF 4 to 60 months of age at
enrollment. The trial was monitored by a Data and Safety Monitoring Board (DSMB)
established by the National Heart, Lung, and Blood Institute. IRB approval and written
informed consent from parents/guardians were obtained at each participating center.
Participant inclusion and exclusion eligibility criteria are detailed in the eMethods. The
upper age limit of 60 months was chosen because previous clinical trials of hypertonic saline
have enrolled children at least 6 years of age9.
Randomization, Blinding and Treatment Regimen
Participants were randomized 1:1 to 7% hypertonic saline vs. 0.9% isotonic saline, based on
random permuted blocks stratified by age (4 to 29 months, 30 to 60 months) and site, via a
secure website. Participants, their families, health care providers and research personnel
were blinded to treatment assignment. Seven percent hypertonic saline (Hyper-Sal™, PARI
Respiratory Equipment, Midlothian, VA) and 0.9% isotonic saline were supplied by
Catalent Pharma Solutions (Somerset, NJ) as identically packaged 4 ml blow-fill seal plastic
ampoules. Each participant was supplied with a PARI Proneb® Ultra compressor with a
PARI LC® Sprint Jr nebulizer equipped with a PARI Baby™ face mask or mouthpiece
(PARI Respiratory Equipment, Midlothian, VA).
Clinical Evaluations
Study visits occurred at enrollment/randomization, and 4, 12, 24, 36 and 48 weeks after
randomization. At the enrollment visit, after pre-treatment with albuterol or levalbuterol, all
participants were evaluated for intolerance to a test dose of 7% hypertonic saline according
to pre-defined criteria10 (see eMethods). Participants who tolerated the test dose were
randomized. Parents/guardians completed a parent questionnaire weekly, and the Cystic
Fibrosis Questionnaire-Revised (CFQ-R)14 and the Treatment Adherence Questionnaire14
quarterly. Further details regarding clinical evaluations are in the eMethods.
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Primary and Secondary Outcomes
The primary outcome was the rate of pulmonary exacerbations (events per person-year),
defined as treatment with oral, inhaled or intravenous antibiotics for 1 or more pre-specified
signs and symptoms within the period 3 days prior to antibiotic start date through antibiotic
stop date (which could include 1 or more antibiotics prescribed for the same pulmonary
exacerbation). The pre-specified signs and symptoms included: (1) oxygen saturation <90%
on room air or ≥5% decline from previous baseline; (2) new lobar infiltrate(s) or atelectasis
on chest radiograph; (3) hemoptysis; (4) increased work of breathing or respiratory rate; (5)
increased cough; (6) worked harder than usual to breathe during physical activity; (7)
increased chest congestion or change in sputum; (8) new or increased adventitial sounds on
lung exam; and (9) weight loss ≥5% of body weight or decrease across 1 major percentile in
weight percentile for age in past 6 months.
Additional efficacy measures included change in weight, height, resting respiratory rate,
room air oxygen saturation and CFQ-R respiratory domain score14 over the 48 week
treatment period; and parent report of daytime cough evaluated at the Week 48 visit15.
Additional evaluations of pulmonary exacerbations included time to first pulmonary
exacerbation as well as number of courses and total number of treatment days with oral,
inhaled, and/or intravenous antibiotics for a pulmonary exacerbation or for any indication.
Safety outcomes included the rate of intolerance to the test dose of hypertonic saline at
enrollment, adverse events and withdrawal rates, and treatment-emergent respiratory
cultures positive for CF pathogens detected through clinical cultures performed at each sites’
microbiology laboratory. All serious adverse events were reviewed by the medical monitor
and the DSMB. Adherence to treatment was assessed by: (1) the number of used study drug
vials returned, (2) the Treatment Adherence Questionnaire completed quarterly and (3) the
weekly parent questionnaire.
Infant Pulmonary Function Testing Substudy
In a substudy at selected sites, infant pulmonary function tests were evaluated as an
exploratory endpoint. Additional inclusion criteria for the infant pulmonary function
substudy included age ≥4 months and < 16 months at enrollment; additional exclusion
criteria included: (1) history of adverse reaction to sedation; (2) clinically significant upper
airway obstruction as determined by the site investigator; (3) severe gastroesophageal reflux,
defined as persistent frequent emesis despite anti-reflux therapy and (4) acute intercurrent
respiratory infection, defined as an increase in cough, wheezing, or respiratory rate with
onset in 2 weeks preceding visit. This substudy was performed at 15 sites previously
certified to perform research quality infant lung function testing. Subjects underwent an
infant pulmonary function test visit a minimum of one day and a maximum of 30 days after
the enrollment visit. Infant pulmonary function tests were performed under sedation at this
visit and at the 48 week visit. For these subjects, randomization was conducted and study
drug was dispensed at the infant pulmonary function test visit rather than at the enrollment
visit. Pulmonary function assessments included functional residual capacity (FRC) by body
plethysmography 16, 17 and measurements of forced expiratory flows (forced expiratory flow
at 75% of vital capacity,FEF75, and mid-maximal forced expiratory flow, FEF25–75) and
volumes (forced expiratory volume in 0.5 seconds, FEV0.5, forced vital capacity, FVC) by
the raised volume rapid thoracoabdominal compression technique18. Additional lung
volumes (residual volume and total lung capacity) were also calculated17. Sites transferred
all infant pulmonary function data to the Therapeutics Development Network Infant
Pulmonary Function Resource Center at the University of North Carolina for expert over-
reading. Acceptable measurements were chosen from the raw data according to published
guidelines4, 18, 19.
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Sample Size Considerations and Statistical Analysis
For the design, we assumed the rate of pulmonary exacerbations in the isotonic saline
(control) group would be 2.22 events/year based on data from a recent large U.S.
observational study of children 0–6 years old33. Using this control rate and an O-Brien-
Fleming boundary function20 for early stopping with a 0.05 level 2-sided hypothesis test, we
calculated a sample size of 150 per group would provide 80% power to detect a rate ratio
(hypertonic saline/isotonic saline) less than or equal to 0.80 (or a relative reduction of at
least 20%).
The primary outcome, pulmonary exacerbation rate, was compared between groups
according to intent-to-treat principles using a Poisson log-linear regression model with log
(observation time) as an offset. Observation time was defined as time since randomization to
last in-clinic visit or phone-call follow-up. (One participant’s observation time was defined
to be ½ day since they did not have an inclinic visit or phone-call follow-up after
randomization.) The rate ratio was also analyzed with adjustment for age category and site.
The number of treatment days with oral, inhaled, or intravenous antibiotics was compared
using a linear regression model of the log of treatment days for participants with greater than
0 treatment days, and estimates were transformed back to the original scale. The probability
of remaining free of a pulmonary exacerbation was estimated by the Kaplan-Meier method
and the hazard ratio for first pulmonary exacerbation with a proportional hazards regression
model. The difference in mean change (week 48 – randomization) in height, weight,
respiratory rate, oxygen saturation, and CFQ-R respiratory domain score was estimated by a
linear regression model with and without adjustment for age category, site, and baseline
measure. The proportion of parental report of daytime cough at week 48 was estimated by a
linear regression model with and without adjustment for age category and site. Mixed effects
analysis was also used to model repeated measurements of height percentile, weight
percentile, respiratory rate and oxygen saturation from all visits. Among infant pulmonary
function substudy participants, the differences between groups in mean change in lung
function indices were evaluated using linear regression with adjustment for baseline lung
function, height, weight, age and gender. Differences in proportions were evaluated by a
normal approximation to the binomial distribution. A two-sided significance level of p<0.05
was used without adjustment for multiple comparisons.
Analyses were conducted using R 2.13.0 (www.r-project.org) at the University of
Washington Collaborative Health Studies Coordinating Center, Seattle, WA, USA (LB and
RK).
RESULTS
Participants Flow and Baseline Characteristics
A total of 321 participants were randomized between April 2009 and October 2010 at 30
sites, 158 to the hypertonic saline group and 163 to the isotonic saline group (Figure 1);
these individuals comprised the intent-to-treat population. Fifteen participants (9%)
withdrew from the hypertonic saline group and 14 (7%) from the isotonic saline group.
Mean duration of study participation was 47 (95% CI, 45, 48) weeks in the hypertonic saline
group and 46 (45, 48) weeks in the isotonic saline group. The baseline characteristics of
participants were similar in the 2 groups (Table 1). About 60% were <30 months of age at
enrollment.
Pulmonary exacerbations and secondary efficacy endpoints
The pulmonary exacerbation rate was 2.3 (95% CI, 2.0, 2.5) per person-year among
participants randomized to hypertonic saline and 2.3 (95% CI, 2.1, 2.6) per person-year
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among participants randomized to isotonic saline. The ratio of the mean pulmonary
exacerbation rate in the hypertonic saline group compared to the isotonic saline group was
0.97 (95% CI, 0.83, 1.13) (Table 2). A Kaplan-Meier plot of time to first pulmonary
exacerbation for both groups is displayed in Figure 2. The hazard ratio for time to first
pulmonary exacerbation in the hypertonic saline group compared to the isotonic saline group
was 0.95 (95% CI, 0.74, 1.21) (Table 2). Among participants with pulmonary exacerbations,
the mean number of total antibiotic treatment days for pulmonary exacerbations was 60
(95% CI 49, 70) in the hypertonic saline group and 52 (95% CI 43, 61) in the isotonic saline
group; the median (25th–75th percentiles) was 41 (24, 71) for the hypertonic saline group
and 35 (21, 56) for the isotonic saline group. The ratio of mean total number of antibiotic
treatment days for a pulmonary exacerbation in the hypertonic saline group compared to the
isotonic saline group was 1.13 (95% CI 0.91, 1.40).
Of the 659 total number of pulmonary exacerbations, 636 (96.6%) were treated with oral, 50
(7.6%) with inhaled and 45 (6.8%) by intravenous antibiotics (not mutually exclusive;
eTable 1). There was no difference between groups in the rates of pulmonary exacerbations
treated by oral, inhaled or intravenous antibiotics as separate categories, or in the number of
courses of oral, inhaled or intravenous antibiotics administered for any indication (eTable 1).
Similarly, the rates of pulmonary exacerbations were similar in the hypertonic saline and
isotonic saline groups among participants <30 months of age and ≥30 months of age at
enrollment (eTable 1).
Significant differences were not detected between groups in weight, height, respiratory rate,
room air oxygen saturation during the study, or in the CFQ-R respiratory domain score or
parent report of daytime cough at the final study visit (Table 3, eTable 2).
Seventy three participants consented to participate in the infant pulmonary function
substudy. The baseline lung function measures of the substudy participants were similar in
the hypertonic saline and isotonic saline groups (Table 1). Acceptable measurements at the
enrollment and final study visit were obtained in 62 (85%) participants for functional
residual capacity, 45 (62%) for raised volume forced expiratory flows and volumes, and 36
(49%) for residual volume. No significant differences between the hypertonic saline and
isotonic saline groups were detected in the raw change from baseline to Week 48 in any of
the pulmonary function measures (Table 4). After adjustment for baseline lung function,
gender, age, height and weight, the mean change in FEV0.5 was 38 ml greater (95% CI 1,
76) in the hypertonic saline group compared to the isotonic saline group (Table 4).
Adherence
Mean adherence to study medications was 75.2% (95% CI, 72.2, 78.2) based on returned
study drug vials among 311 participants. Based on the weekly parent questionnaire
(available from 309 participants), mean adherence to twice daily dosing was 91% (95% CI,
89, 93), and to at least once daily dosing was 96% (95% CI, 95, 98). Based on the quarterly
treatment adherence questionnaire (available from 312 participants), mean adherence to
twice daily dosing was 88% (95% CI 85, 90), to using at least 6 days per week was 86%
(95% CI 83, 89), and to nebulizing 10 or more minutes per treatment was 89% (95% CI 86,
92). Adherence was similar between the 2 groups (eTable 3).
Safety
Of the participants who received the test dose of 7% hypertonic saline at enrollment, 2 were
found to be intolerant and were not randomized. Serious adverse events are shown in Table
5. In the hypertonic saline group, there were 56 serious adverse events among 33
participants. In the isotonic saline group, there were 74 events among 43 participants. No
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significant differences between groups in the proportion of participants with serious adverse
events of each category were detected. The most common serious adverse event in both
groups was cough or increased cough, occurring in 8% of participants in the hypertonic
saline group and 10% of participants in the isotonic saline group.
A significant difference between groups was not detected in the proportion of adverse events
of moderate or severe severity occurring in >10% of participants in either group (eTable 4).
The proportion of participants with new isolation of bacteria from respiratory cultures
during the study period is shown in eTable 5; statistically significant differences between
groups were not detected.
DISCUSSION
This is to our knowledge the first clinical trial assessing a chronic non-antimicrobial
pulmonary therapy in children with CF < 6 years of age. Hypertonic saline did not reduce
the rate of pulmonary exacerbations in these young children. In addition, hypertonic saline
did not demonstrate any significant effects on secondary endpoints including weight, height,
respiratory rate, oxygen saturation, antibiotic use, or parent report of respiratory signs and
symptoms.
Previous studies in older children and adults with CF have documented benefits of inhaled
hypertonic saline 7–9, 21, 22. In the multi-center Australian study in patients >6 years of age,
treatment with hypertonic saline did not demonstrate a significant effect on the primary
outcome measure, the rate of change of lung function, but was associated with a significant
reduction in the rate of pulmonary exacerbations9. Pulmonary exacerbation rate was chosen
as the primary outcome in the current trial because of the important effect observed in the
Australian hypertonic saline trial9 and because pulmonary exacerbations are a clinical
endpoint (affecting how a person feels, functions or survives)23 that have been associated
with survival in CF24, 25. The pulmonary exacerbation definition in the current study
differed from that in the Australian study, in which pulmonary exacerbations were defined
as treatment with intravenous antibiotics for pre-defined signs and symptoms, or the
occurrence of those signs and symptoms independent of treatment. Our definition, similar to
that used in 2 prior studies in young CF patients26, 27, was designed to capture all events in
which several days of new respiratory signs or symptoms triggered treatment with oral,
inhaled or intravenous antibiotics, the standard clinical practice for CF patients in this age
range. In the current study, while the vast majority of pulmonary exacerbations were treated
with oral antibiotics, there was no difference between the 2 groups in the rate of
exacerbations even if limited to those treated with intravenous antibiotics, nor in respiratory
symptoms. Thus, it is unlikely that the difference in our results is due to a different
pulmonary exacerbation definition.
As opposed to older patients, pulmonary exacerbations in infants and young children are
frequently triggered by viral infections. It is thus possible that hypertonic saline has less
ability to prevent exacerbations in children <6 years of age than in older CF patients.
Previous studies have demonstrated that viral infections occur at similar rates in CF and non
CF infants, but that the severity and duration of symptoms is increased in CF patients28.
Thus hypertonic saline, even if not affecting the rate of pulmonary exacerbations in young
children with CF, might reduce the severity and duration of symptoms, similar to its
observed effect in non-CF infants with bronchiolitis29. However, the current study provides
no evidence that the severity or duration of pulmonary exacerbations was influenced by
hypertonic saline, as parent-reported respiratory signs and symptoms and days of antibiotic
therapy did not differ between groups.
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We estimated the expected pulmonary exacerbation rate based on data from an ongoing U.S.
observational study of early CF lung disease, the EPIC Observational Study30. The rate of
pulmonary exacerbations in the current study (mean 2.3 events per person-year) was very
similar to that observed in the EPIC Observational Study (2.22 per person-year), indicating
that the trial was adequately designed to observe the predefined treatment effect. In addition,
the participants in the current study had baseline characteristics (Table 1) similar to the
overall patient population in the U.S. CF National Patient Registry in this age range,
suggesting that our findings are generalizable to the overall CF population <6 years of age.
This study was designed to primarily demonstrate an effect on clinically meaningful events
rather than on prevention of lung disease progression. Our choice of endpoints was limited
by the fact that validated outcome measures commonly used in older patients are lacking for
very young children with CF. It could be argued that an intervention targeting mucociliary
clearance in a population with limited clinical lung disease is unlikely to improve any short-
term clinical outcome measure and that a more realistic goal would be to slow progression
of structural airway damage or improve lung function. We conducted a substudy of infant
pulmonary function tests as an exploratory endpoint at selected sites in order to gain
information to adequately power future studies using this endpoint. Interestingly, the mean
change in FEV0.5 over the treatment period was significantly greater in the hypertonic saline
group compared to the isotonic saline group. While these findings may be due to chance,
they also may reflect improvement in airflow limitation in the hypertonic saline group that
was not detectable with our primary or secondary outcome measures. Due to the relatively
silent nature of early CF lung disease, sensitive endpoints are critical.
When the current study was being planned, protocols for chest CT and multiple breath
washout for multiple age ranges were not adequately developed and multi-center experience
in infants and young children with these techniques was limited. The availability of
appropriate multi-center protocols and networks as well as increased expertise in these
techniques suggests that adequately powered trials using physiologic measures as outcomes
may be conducted. Future studies of hypertonic saline in young children utilizing these or
other endpoints will allow evaluation of the effects of this treatment on early structural
airway damage and lung function, including ventilation inhomogeneity.
In both the current study and the Australian hypertonic saline trial, isotonic saline served as
the control agent. It is possible that isotonic saline has a more pronounced effect on mucus
hydration in the very young than in older patients. In addition, participants in both arms
received albuterol prior to each dose of study drug. Both of these factors might have limited
our ability to detect a difference in outcomes between the 2 groups. The fact that the
exacerbation rate in the control group was very similar to that in an untreated historical
cohort would suggest that there was not an important effect of isotonic saline on the primary
endpoint. Unfortunately, it is not feasible to perform a true placebo controlled study of
hypertonic saline as no inhaled agent is completely inert.
Treatment with hypertonic saline was well tolerated and adherence to therapy was overall
high. Chronic inhaled therapy could pose a risk of new acquisition of bacterial pathogens if
nebulizers are not properly cleaned and disinfected31. As this study did not include an
untreated control group, this potential side effect of inhalation therapy cannot be excluded.
However, the rate of new acquisition of organisms did not differ significantly from that
reported in the CF Registry or in the EPIC Observational Study32. Therefore, while not
showing a decrease in pulmonary exacerbation rate, this study supports previous smaller
series demonstrating that inhalation of hypertonic saline is safe in infants and young
children.
Rosenfeld et al. Page 8













In conclusion, among infants and children with CF less than 6 years old, the use of inhaled
hypertonic saline compared with isotonic saline did not reduce the rate of pulmonary
exacerbations over 48 weeks of treatment. Further study with physiologic endpoints is
warranted to better understand how this drug may slow progression of structural airway
damage or improve lung function in the youngest population.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Kaplan-Meier Plot of Time to First Exacerbation by Treatment Group
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Table 1
Baseline Characteristics of Participants by Treatment Group
N (%) or mean (SD)
Hypertonic saline (N=158) Isotonic Saline (N = 163)
Age, yrs 2.2 (1.4) 2.3 (1.5)
Age category
 <30 mo 95 (60.1%) 96 (58.9%)
 ≥30 mo 63 (39.9%) 67 (41.1%)
Male 84 (53%) 92 (56%)
CFTR genotype
 N available 153 158
 Homozygous DeltaF508 82 (53.6%) 88 (55.7%)
 Compound heterozygote DeltaF508 34 (22.2%) 36 (22.8%)
 Other 37 (24.2%) 34 (21.5%)
Race/Ethnicity
 Non-Hispanic Caucasian 149 (94.3%) 153 (93.9%)
 Hispanic 6 (3.8%) 7 (4.3%)
 Other 3 (1.9%) 3 (1.8%)
Sweat chloride, mEq/L1 95.2 (18.0) 94.7 (18.9)
Weight, kg 12.2 (4.1) 12.5 (4.1)
Weight percentile 39.7 (28.1) 43.0 (29.1)
Height, cm 84.8 (14.8) 85.7 (15.0)
Height percentile 36.9 (27.0) 39.9 (28.1)
Positive newborn screen2 101 (75%) 92 (68%)
Chronic medication use
 Dornase alfa 61 (39%) 65 (40%)
 Albuterol/Levalbuterol 115 (73%) 120 (74%)
Positive respiratory culture3
 Pseudomonas aeruginosa 60 (38.0%) 69 (42.3%)
 S. aureus 98 (62.0%) 124 (76.1%)
 MRSA 5 (3.2%) 11 (6.8%)
 S. maltophilia 25 (15.8%) 35 (21.5%)
 A. xylosoxidans 4 (2.5%) 3 (1.8%)
 B. Cepacia 0 (0%) 0 (0%)
Resting respiratory rate, bpm 31 (8.8) 30 (9.2)
Oximetry, % 98 (1.4) 98 (1.5)
N (%) with a parent-reported daytime cough4 27 (17.1%) 24 (14.7%)
CFQ-R respiratory domain score5 86.9 (13.9) 87.7 (12.3)
Consented to infant pulmonary function substudy 36 37
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N (%) or mean (SD)
Hypertonic saline (N=158) Isotonic Saline (N = 163)
 FRC6 (ml) 198 (50) 216 (59)
 FEV0.5 7(ml) 276 (68) 282 (66)
 FEF75 7(ml/sec) 303 (132) 284 (105)
 FEF25–75 7(ml/sec) 592 (212) 578 (172)
 RV/TLC 8 0.3 (0.1) 0.3 (0.1)
1
Data available from 125 participants in hypertonic saline group and 126 in isotonic saline group
2
Data available from 135 participants in hypertonic saline group and 135 in isotonic saline group
3
P. aeruginosa isolated from respiratory culture at or at any time prior to randomization. For other organisms, positive culture at or within 24




Scores range from 0 to 100, with a higher score indicating milder symptoms. Data available from 156 participants in hypertonic saline group and
157 participants in isotonic saline group
6
FRC, functional residual capacity; data available from 36 participants in hypertonic saline group and 37 in isotonic saline group
7
FEV0.5, forced expiratory volume in 0.5 seconds; FEF75, forced expiratory flow at 75% of vital capacity; FEF25–75, mean forced expiratory
flow between the 25th and 75th percent of vital capacity; data available from 29 participants in hypertonic saline group and 32 in the isotonic
saline group
8
RV/TLC, ratio of residual volume to total lung capacity; data available from 27 participants in hypertonic saline group and 29 in isotonic saline
group
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Table 2
Comparison of pulmonary exacerbation rates and related endpoints
Hypertonic saline / isotonic saline ratio (95%
CI)
Hypertonic saline Isotonic saline Unadjusted Adjusted1
Pulmonary exacerbations rate2, events/person-
year (95% CI). 124 participants randomized to
hypertonic saline had 321 pulmonary
exacerbations during 142 person-years of follow-
up; 129 participants randomized to isotonic saline
had 338 pulmonary exacerbations during 145
person-years of follow-up.
2.3 (2.0, 2.5) 2.3 (2.1, 2.6) 0.97 (0.83,1.1) 0.98 (0.84, 1.15)
Total number of treatment days for a pulmonary
exacerbation3, mean (95% CI)
60 (49, 70) 52 (63, 71) 1.13 (0.91,1.40) 1.11 (0.89,1.37)
Hazard ratio for first pulmonary exacerbation, hypertonic saline/isotonic saline (95% CI) 0.94 (0.74, 1.21) 0.94 (0.73, 1.22)
1
Adjusted for age category and site.
2
Includes log of observation time as an offset in the Poisson regression model
3
Among participants with pulmonary exacerbations
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